UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | | |
| Date of Report (Date of Earliest Event Reported): | | August 25, 2004 |
Anadys Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)| | | | | |
| Delaware | | 000-50632 | | 22-3193172 |
| |
| |
|
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (I.R.S. Employer
Identification No.) |
| | | | | |
| 3115 Merryfield Row, San Diego, CA | | | | 92121 |
| | | |
|
| (Address of principal executive offices) | | | | (Zip Code) |
| | | |
| Registrant’s telephone number, including area code | | (858) 530-3600 |
Not Applicable
Former name or former address, if changed since last report
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
(d) On July 22, 2004, the Company’s Board of Directors approved the appointment of Douglas E. Williams, Ph.D. to serve as a member of its Board of Directors. Dr. Williams’ appointment to the Board of Directors was effective August 25, 2004. Dr. Williams’ potential Board of Director Committee appointments have not been determined as of August 31, 2004, the date of the filing of this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | Anadys Pharmaceuticals, Inc. |
| | | (Registrant) |
| | | | | |
August 31, 2004 | | By: | | /s/ Michael J. Kamdar |
| | | |
|
| | | | Name: Michael J. Kamdar |
| | | | Title: Senior Vice President, Corporate Development and Finance |
